FLT3 inhibitors in acute myeloid leukemia

References

• van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell Biol.10, 251–337 (1994).
   PubMedGoogle Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell103(2), 211–225 (2000).
   PubMed Web of Science ®Google Scholar
• Ben-Neriah Y, Daley GQ, Med-Masson AM et al. The chronic myelogenous leukemia specific p210 protein is the product of bcr/abl hybrid gene. Science233(4760), 212–214 (1986).
   PubMed Web of Science ®Google Scholar
• Cools J, DeAngelo DJ, Gotlieb J et al. A tyrosine kinase created by the fusion of the PDGFR and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med.348(13), 1201–1241 (2003).
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med.352(17), 1779–1790 (2005).
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J et al. Activating mutations in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell7(4), 387–397 (2005).
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature434(7037), 1144–1148 (2005).
   PubMed Web of Science ®Google Scholar
• Gilliland DG. Molecular genetics of human leukemia. Leukemia1(Suppl.), S7–S12 (1998).
   Google Scholar
• Gilliland DG, Griffin JD. The role of FLT3 in hematopoiesis and leukemia. Blood100(5), 1532–1542 (2002).
   PubMed Web of Science ®Google Scholar
• Rosnet O, Schiff C, Pebusque MJ et al. Human FLT/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood82(4), 1110–1119 (1993).
   PubMed Web of Science ®Google Scholar
• Small D, Levenstein M, Kim E et al. STK-1, the human homolog of Flk2/Flt3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc. Natl Acad. Sci. USA91(2), 459–463 (1994).
   PubMed Web of Science ®Google Scholar
• Hannum C, Culpepper J, Campbell D et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of hematopoietic stem cells and is encoded by variant RNAs. Nature368(6472), 643–648 (1994).
   PubMed Web of Science ®Google Scholar
• Lyman SD, James L, Lee Y et al. Essential role of human homologue of murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood83(10), 2795–2801 (1994).
   PubMed Web of Science ®Google Scholar
• Dosil M, Wang S, Lemischka IR. Mitogenic signaling and substrate specificity of FLK2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol. Cell Biol.13(10), 6572–6585 (1993).
   PubMed Web of Science ®Google Scholar
• Rosnet O, Buhring HJ, deLapeyriere O et al. Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Hematol.95(3–4), 218–223 (1996).
   PubMed Web of Science ®Google Scholar
• Lavagna-Sevenier C, Marchetto S, Birnbaum D et al. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia12(3), 301–310 (1998).
   PubMed Web of Science ®Google Scholar
• Lavagna-Sevenier C, Marchetto S, Birnbaum D et al. The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells. J. Biol. Chem.273(24), 14962–14967 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang S, Mantel C, Broxmeyer HE. Flt3 signaling involves tyrosyl phosphorylation of SPH-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J. Leukoc. Biol.65(3), 372–380 (1999).
   PubMed Web of Science ®Google Scholar
• Marchetto S, Fournier E, Beslu N et al. SHC and SHIP phosphorylation and interaction in response to activation of FLT3 receptor. Leukemia13(9), 1374–1382 (1999).
   PubMed Web of Science ®Google Scholar
• Zhang S, Fukuda S, Lee Y et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J. Exp. Med.192(5), 719–729 (2000).
   PubMed Web of Science ®Google Scholar
• Small D, Levenstein M, Kim E et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc. Natl Acad. Sci. USA91(2), 459–463 (1993).
   Web of Science ®Google Scholar
• Mackarehtschian K, Hardin JD, Moore KA et al. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity3(1), 147–161 (1995).
   PubMed Web of Science ®Google Scholar
• McKenna HJ, Stocking KL, Miller RE et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood95(11), 3489–3497 (2000).
   PubMed Web of Science ®Google Scholar
• Ray RJ, Paige CJ, Furlonger C et al. Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. Eur. J. Immunol.26(7), 1504–1510 (1996).
   PubMed Web of Science ®Google Scholar
• Veiby OP, Jacobson FW, Cui L et al. The flt3 ligand promotes the survival of hematopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-α and TNF-β. J. Immunol.157(7), 2953–2960 (1996).
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE, Lu L, Cooper S et al. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp. Hematol.23(10), 1121–1129 (1996).
   Web of Science ®Google Scholar
• Hirayama F, Lyman SD, Clark SC et al. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood85(7), 1762–1768 (1995).
   PubMed Web of Science ®Google Scholar
• Sitnicka E, BuzaVidas N, Larsson S et al. Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood102(3), 881–886 (2003).
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Ohno R, Ueda R et al. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene21(16), 2555–2563 (2002).
   PubMed Web of Science ®Google Scholar
• Abu-Duhier FM, Goodeve AC, Wilson GA et al. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukemia. Br. J. Hematol.113(4), 983–988 (2001).
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach C, Kern W et al. Prognostic relevance of FLT3-TDK mutations in AML: the combination matters – an analysis of 3082 patients. Blood111(5), 2527–2537 (2008).
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kiyoi H, Nakano Y et al. Activation mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood97(8), 2434–2439 (2001).
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Towatari M, Yokota S et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia12(9), 1333–1337 (1998).
   PubMed Web of Science ®Google Scholar
• Mizuki M, Fenski R, Halfter H et al. FLt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by Ras and STAT5 pathways. Blood96(12), 3907–3914 (2000).
   PubMed Web of Science ®Google Scholar
• Mizuki M, Schwabe J, Steur C et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood101(8), 3164–3173 (2003).
   PubMed Web of Science ®Google Scholar
• Scheijen B, Ngo HT, Kang H et al. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene23(19), 3338–3349 (2004).
   PubMed Web of Science ®Google Scholar
• Choudhary C, Schwable J, Brandts C et al. AML-associated Flt3 kinase domain mutations show signal transduction differences in comparison to Flt3 ITD mutations. Blood106(1), 265–273 (2005).
   PubMed Web of Science ®Google Scholar
• Stock W, Najib K, Moser BK et al. High incidence of FLT3 mutation in adults with acute promyelocytic leukemia (APL): correlation with diagnostic features and treatment outcome. J. Clin. Oncol.26 (2008) (Abstract 7002).
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Naoe T, Yokota S et al. Internal tandem repeat duplications of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia11(9), 1447–1452 (1997).
   PubMed Web of Science ®Google Scholar
• Arrigoni P, Beretta C, Silvestri D et al.FLT3 internal tandem repeat duplication in childhood acute myeloid leukemia: association of hyperleukocytosis in acute promyelocytic leukemia. Br. J. Hematol.120(1), 89–92 (2003).
   PubMed Web of Science ®Google Scholar
• Noguera NI, Breccia M, Divona M et al. Alterations of FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia16(11), 2185–2189 (2002).
   PubMed Web of Science ®Google Scholar
• Shih LY, Kuo MC, Liang DC et al. Internal tandem repeat duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) in acute promyelocytic leukemia. Cancer98(6), 1206–1216 (2003).
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Germing U, Hartmann F et al. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia19(6), 978–983 (2005).
   PubMed Web of Science ®Google Scholar
• Levis M, Small D. ITDoes matter in leukemia. Leukemia17(9), 1738–1752 (2003).
   PubMed Web of Science ®Google Scholar
• Murphy KM, Levis M, Hafez MJ et al. Detection of FLT3 internal tandem repeat duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J. Mol. Diagn.5(2), 96–102 (2003).
   PubMed Web of Science ®Google Scholar
• Mishinchi S, Woods WG, Stirewalt DL et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood97(1), 89–94 (2001).
   PubMed Web of Science ®Google Scholar
• Froeling S, Schlenk RF, Breitruck J et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group. Blood100(13), 4372–4380 (2002).
   PubMed Web of Science ®Google Scholar
• Scholl S, Theuer C, Scheble V et al. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 years with acute myeloid leukemia. Eur. J. Hematol.80(3), 208–215 (2008).
   PubMed Web of Science ®Google Scholar
• Gale RE, Green C, Allen C et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood111(5), 2776–2784 (2008).
   PubMed Web of Science ®Google Scholar
• Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J. Clin. Oncol.23(23), 5386–5403 (2005).
   PubMed Web of Science ®Google Scholar
• Li Y, Li H, Wang MN et al. Suppression of leukemia expressing wild-type or ITD-mutant Flt3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood104(4), 1137–1144 (2004).
   PubMed Web of Science ®Google Scholar
• Traxler P, Bold G, Buchdunger E et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev.21(6), 499–512 (2001).
   PubMed Web of Science ®Google Scholar
• Fiedler W, Mesters R, Tinnefeld H et al. A Phase II clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood102(8), 2763–2767 (2003).
   PubMed Web of Science ®Google Scholar
• Giles FJ, Cooper MA, Silverman L et al. Phase II study of SU5416-a small molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor- in patients with refractory myeloproliferative diseases. Cancer97(8), 1920–1928 (2003).
   PubMed Web of Science ®Google Scholar
• O’Farrell AM, Yuen HA, Smilich B et al. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk. Res.28(7), 679–689 (2004).
   PubMed Web of Science ®Google Scholar
• Levis M, Small D. Small molecule FLT3 tyrosine kinase inhibitors. Curr. Pharm. Des.10(11), 1183–1193 (2004).
   PubMed Web of Science ®Google Scholar
• Fiedler W, Serve H, Dohner H et al. A Phase I study of SU-11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood105(5), 986–993 (2005).
   PubMed Web of Science ®Google Scholar
• Yee KW, Schittenhelm M, O’Farrell AM et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT ITD-positive leukemic cells. Blood104(13), 4202–4209 (2004).
   PubMed Web of Science ®Google Scholar
• Weisberg E, Boulton C, Kelly LM et al. Inhibition of mutant FLT3 receptors in leukemia cells by small molecule tyrosine kinase inhibitor PKC412. Cancer Cell1(5), 433–443 (2002).
   PubMed Web of Science ®Google Scholar
• Stone RM, Fischer T, Paquette R et al. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under age 61 (abstract). Blood(ASH Annual Meeting Abstracts)108, 157 (2006).
   Google Scholar
• Stone RM, DeAngrlo DJ, Klimek V et al. Patients with acute myeloid leukemia and activating mutation in FL3 respond to small molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood105(1), 54–60 (2005).
   PubMed Web of Science ®Google Scholar
• Levis M, Allebach J, Tse KF et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood99(11), 3885–3891 (2002).
   PubMed Web of Science ®Google Scholar
• Smith BD, Levis M, Beran M et al. Single agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed acute myeloid leukemia. Blood103(10), 3669–3676 (2004).
   PubMed Web of Science ®Google Scholar
• Levis M, Pham R, Smith BD et al.In vitro studies of FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood104(4), 1145–1150 (2004).
   PubMed Web of Science ®Google Scholar
• Kelly LM, Yu JC, Boulton CL et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell1(5), 421–432 (2002).
   PubMed Web of Science ®Google Scholar
• Pandey A, Volkots DL, Seroogy JM et al. Identification of orally active, potent, and selective 4-piper-azinylquinazoline as antagonists of platelet-derived growth factor receptor tyrosine kinase family. J. Med. Chem.45(17), 3772–3793 (2002).
   PubMed Web of Science ®Google Scholar
• De Angelo D, Stone RM, Heaney ML et al. Phase 1 clinical results of tandutinib (MLN518), a novel FLT3 antagonist in patients with acute myelogenous leukemia or high risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood108(12), 3674–3681 (2006).
   PubMed Web of Science ®Google Scholar
• De Angelo D, Stone R, Heaney M et al. Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with acute myeloid leukemia (AML) bearing a FLT3 internal tandem duplication (ITD) mutation. Blood104(11) (2004) (Abstract 496).
   Google Scholar
• Li L, Piloto O, Nguyen HB et al. Knock-in of an internal tandem repeat duplication mutation into murine FLT3 confers myeloproliferative disease in mouse model. Blood111(7), 3849–58 (2008)
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nagar B et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI-571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell2(2), 117–125 (2002).
   PubMed Web of Science ®Google Scholar
• Cools J, Mentens N, Furet P et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res.64(18), 6385–6389 (2004).
   PubMed Web of Science ®Google Scholar
• Bagrintseva K, Schwab R, Kohl TM et al. Mutations in the tyrosine kinase domain of Flt3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in Flt3-ITD-transformed hematopoietic cells. Blood103(6), 2266–2275 (2004).
   PubMed Web of Science ®Google Scholar